432
Participants
Start Date
December 6, 2013
Primary Completion Date
September 12, 2016
Study Completion Date
May 2, 2019
Momelotinib
Momelotinib tablet administered orally once daily
Ruxolitinib
Ruxolitinib tablets administered orally twice daily
Placebo to match momelotinib
Placebo to match momelotinib tablets administered orally once daily
Placebo to match ruxolitinib
Placebo to match ruxolitinib tablets administered orally twice daily
Phoenix
Escondido
Stanford
Jacksonville
Atlanta
Chicago
Baltimore
Boston
St Louis
Durham
Seattle
Darlinghurst
Parkville
Saint Leonards
Brisbane
Herston
Adelaide
Bedford Park
Frankston
Melbourne
Perth
Vienna
Charleroi
Antwerp
Leuven
Liège
Pleven
Plovdiv
Rousse
Sofia
Varna
Edmonton
Vancouver
Hamilton
Toronto
Hradec Králové
Brno
Ostrava
Aalborg
Herlev
Pierre-Bénite
Toulouse
Le Kremlin-Bicêtre
Lens
Lille
Marseille
Nantes
Paris
Pessac
Villejuif
München
Leipzig
Dresden
Düsseldorf
Freiburg im Breisgau
Hamburg
Mainz
Mannheim
Budapest
Debrecen
Kaposvár
Afula
Ashkelon
Haifa
Jerusalem
Tel Aviv
Ōgaki
Kitaku Sapporo
Osaka
Ōsaka-sayama
Bunkyo-ku, Tokyo
Fukushima
Kumamoto
Matsuyama
Okayama
Maastricht
Nijmegen
Rotterdam
Utrecht
Poznan
Krakow
Lublin
Warsaw
Gdansk
Bialystok
Brzozów
Chorzów
Lodz
Arad
Brasov
Bucharest
Cluj-Napoca
Iași
Singapore
Seoul
Majadahonda
Pamplona
Badalona
Barcelona
Valencia
Zaragoza
Lund
Örebro
Stockholm
Uddevalla
Kaohsiung City
Leicester
London
Manchester
Newcastle upon Tyne
Oxford
Cardiff
Northern Ireland
Nottingham
Sierra Oncology LLC - a GSK company
INDUSTRY